Cargando…

Basic and clinical immunology – 3030. Subcutaneous immunoglobulin therapy: An option for patients who have experienced thrombotic complications with intravenous therapy

Detalles Bibliográficos
Autores principales:	Moss, Leslie Anne, Keith, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	World Allergy Organization 2013
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643292/ http://dx.doi.org/10.1186/1939-4551-6-S1-P205

Ejemplares similares

Treatment costs associated with hospital-based intravenous immunoglobulin therapy compared to home-based subcutaneous immunoglobulin therapy in a cohort of paediatric patients with primary immunodeficiency
por: Ducruet, Thierry, et al.
Publicado: (2011)

Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
por: Martin, Adriana, et al.
Publicado: (2012)

Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
por: Martin, Adriana, et al.
Publicado: (2012)

Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada
por: Gerth, William C, et al.
Publicado: (2014)

Experience with subcutaneous immunoglobulin therapy in two pediatric cases of immune thrombocytopenia purpura
por: Chapdelaine, H, et al.
Publicado: (2012)

Improved quality of life with home therapy with subcutaneous immunoglobulins for patients with secondary hypogammaglobulinaemia
por: Levasseur, Marie-Claude, et al.
Publicado: (2012)

Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
por: Kobrynski, Lisa
Publicado: (2012)

Intravenous immunoglobulin therapy could have efficacy in severe sepsis
por: Kim, Ahmin, et al.
Publicado: (2013)

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies
por: Canessa, Clementina, et al.
Publicado: (2016)

Circular RNA circCOL6A3_030 is involved in the metastasis of gastric cancer by encoding polypeptide: circCOL6A3_030 promotes metastasis.
por: Geng, Xiaoge, et al.
Publicado: (2021)

A pilot study of quality of life, mood, sleepiness and fatigue in patients with primary humoral immunodeficiency transitioning to subcutaneous immunoglobulin therapy
por: Pourshahnazari, Persia, et al.
Publicado: (2014)

Complete Genome Sequence of Streptococcus pneumoniae Serotype 19F Strain EF3030
por: Junges, R., et al.
Publicado: (2019)

Subcutaneous Immunoglobulins are a Valuable Treatment Option in Myasthenia Gravis
por: Garnero, Martina, et al.
Publicado: (2018)

Pemphigoid gestationis and intravenous immunoglobulin therapy()
por: Yang, Anes, et al.
Publicado: (2018)

Scleromyxedema with Subcutaneous Nodules: Successful Treatment with Thalidomide and Intravenous Immunoglobulin
por: Dolenc-Voljč, M., et al.
Publicado: (2013)

Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert’s and patient’s perspective
por: Jonaitis, Laimas, et al.
Publicado: (2021)

Total laparoscopic hysterectomy of very enlarged uterus (3030 g): case report and review of the literature
por: Ceccaroni, Marcello, et al.
Publicado: (2014)

Immunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder Cancer
por: Ingersoll, Molly A., et al.
Publicado: (2018)

Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
por: Gerth, William C, et al.
Publicado: (2014)

Allergic diseases of the skin and drug allergies – 2027. Successful treatment with intravenous immunoglobulin and prednisolone pulse therapy of toxic epidemal necrolysis and Stevens-Johnson Syndrome
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Pneumococcal Antibody Titers: A Comparison of Patients Receiving Intravenous Immunoglobulin Versus Subcutaneous Immunoglobulin
por: Abghari, Pamella F., et al.
Publicado: (2017)

Intravenous immunoglobulin therapy for COVID-19 ARDS
por: Wilfong, Erin M, et al.
Publicado: (2022)

Intravenous immunoglobulin G therapy for neonatal hyperbilirubinemia
por: Rasiah, Saisujani, et al.
Publicado: (2023)

Subcutaneous Immunoglobulin-G Replacement Therapy with Preparations Currently Available in the United States for Intravenous or Intramuscular Use: Reasons and Regimens
por: Chouksey, Akhilesh, et al.
Publicado: (2005)

Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
por: Martin, A, et al.
Publicado: (2013)

Is there a Role of Intravenous Immunoglobulin in Immunologic Recurrent Pregnancy Loss?
por: Yang, Xiuhua, et al.
Publicado: (2020)

3030 Symptom profile of chronic rhinosinusitis versus obstructive sleep apnea in a tertiary rhinology clinic
por: Yong Ji, Keven Seung, et al.
Publicado: (2019)

Initiation of immunoglobulin therapy by subcutaneous administration in immunodeficiency patients naive to replacement therapy
por: Koterba, Alan P, et al.
Publicado: (2014)

Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies
por: Kaminski, Monica A., et al.
Publicado: (2020)

Basic and clinical immunology – 3015. Nonspecific defense factors in premature infants with pneumonia
por: Alimova, Kamola, et al.
Publicado: (2013)

Basic and clinical immunology – 3016. Successful desensitization to oxaliplatin for metastic colorectal carcinoma
por: Buddiga, Praveen, et al.
Publicado: (2013)

Basic and clinical immunology – 3025. Suppression of eosinphil activation by levocetirizine hydrochloride in vivo
por: Kawaguchi, Kenichiro, et al.
Publicado: (2013)

Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
por: Scheuerlein, Philipp, et al.
Publicado: (2018)

Immunological evidence and regulatory potential for cell-penetrating antibodies in intravenous immunoglobulin
por: Sali, Aggeliki D, et al.
Publicado: (2015)

Predictors of nonresponse to intravenous immunoglobulin therapy in Kawasaki disease
por: Park, Hyo Min, et al.
Publicado: (2013)

Intravenous immunoglobulin therapy in COVID-19-related encephalopathy
por: Muccioli, Lorenzo, et al.
Publicado: (2020)

Basic and clinical immunology – 3034. Peculiarities of parameters immune system in juvenile rheumatoid arthritis
por: Musakhodjaeva, Diloram Abdullaevna, et al.
Publicado: (2013)

Basic and clinical immunology – 3021. Inhibitory action of levocetirzine hydrochloride on eosinophil actication in vitro
por: Furuta, Atsuko, et al.
Publicado: (2013)

Basic and clinical immunology – 3018. Immunocap vs. skin prick testing for inhalant allergens
por: Kumar, Prem, et al.
Publicado: (2013)

In-depth interviews of patients with primary immunodeficiency who have experienced pump and rapid push subcutaneous infusions of immunoglobulins reveal new insights on their preference and expectations
por: Cozon, Grégoire Jacques Noël, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7i4klm21388arnf1kvs21as9sq